Dr. Bhatt has received research grants from Abbott, Amarin, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis and the Medicines Company.
Brigham and Women's Hospital Heart & Vascular Center, and Harvard Medical School
|Program Name||Last Air Date||Hosts/Guests|
|New Opportunities to Improve Management of Patients with or at High Risk of ASCVD Events||06/24/2019|
|New Options & Strategies for CV Risk Reduction in Diabetes: What the Data Tell Us|
|New Opportunities to Improve Management of Patients with or at High Risk of ASCVD Events|
|New Options to Reduce Cardiovascular Events in Atherosclerotic Cardiovascular Disease (ASCVD)||06/23/2019|
|Challenging Case Studies: Percutaneous Coronary Interventions and Post-discharge Antithrombotic M...||12/01/2018|
|Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events||06/22/2019|
You need to be logged in to save this episode to a playlist.
You must be logged in to display playlists.